Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain [PDF]
Neurology and TherapyBackground Despite considerable evidence for the efficacy and safety of stiripentol in Dravet syndrome (DS), some aspects of stiripentol use remain challenging in clinical practice, such as dose titration and the adjustment of concomitant antiseizure ...
Juan José García-Peñas +5 more
doaj +3 more sources
Journal of Pharmaceutical Analysis, 2021 The new antiepileptic drugs perampanel, retigabine, rufinamide and stiripentol have been recently approved for different epilepsy types. Being them an innovation in the antiepileptics armamentarium, a lot of investigations regarding their pharmacological
Sara Meirinho +4 more
doaj +2 more sources
The Difficult Journey of a Child with Dravet Syndrome: Perspectives from a Parent and the Neuropaediatrician [PDF]
Neurology and TherapyDravet syndrome (DS) is a rare and severe form of epilepsy, characterised by recurrent seizures that begin during the first year of life, leading to motor, cognitive and behavioural impairments.
Romain Reboux, Silvia Napuri
doaj +2 more sources
A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form [PDF]
Journal of Analytical Methods in Chemistry, 2014 A rapid, simple, sensitive, and accurate isocratic reversed-phase stability-indicating high performance liquid chromatography method has been developed and validated for the determination of stiripentol and its degradation product in its bulk form and ...
Hany W. Darwish +5 more
doaj +2 more sources
Lipid Nanoparticles with Stiripentol and Cannabidiol Oil: From Rational Optimization to Preclinical Characterization [PDF]
PharmaceuticsBackground/Objectives: Dravet Syndrome (DS) is a severe form of epilepsy that typically manifests in the first year of life and often requires polytherapy with two or more antiseizure medications (ASMs) to achieve adequate seizure control.
Sebastián Scioli-Montoto +10 more
doaj +2 more sources
Epilepsia OpenObjectives Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as ...
Renzo Guerrini +4 more
doaj +2 more sources
Antiseizure medication prescribing in people with Dravet syndrome: An analysis of real‐time administrative data [PDF]
Epilepsia OpenSince 2018, three new antiseizure medications (ASMs) received FDA approval for Dravet syndrome (DS) in the U.S: cannabidiol, stiripentol, and fenfluramine. Yet, the uptake of these ASMs in routine clinical practice is unknown. We use new ICD‐10 codes for
Kevin Y. Xu +3 more
doaj +2 more sources
International Journal of Nanomedicine, 2015 Rong Lu,1 Shan Liu,1 Qilin Wang,1 Xia Li1,2 1School of Ocean, Shandong University, Weihai, 2School of Pharmaceutical Sciences, Shandong University, Jinan, People’s Republic of China Abstract: Oral administration remains a significant challenge
Lu R, Liu S, Wang Q, Li X
doaj +1 more source
Stiripentol directly attenuates immunosuppression of tumor-infiltrating myeloid cells to potentiate anti-PD-1 efficacy [PDF]
BMC CancerBackground Immune checkpoint blockade (ICB) therapy demonstrates significant efficacy across multiple malignancies, yet resistance remains prevalent.
Zhiqi Xie +10 more
doaj +2 more sources
Stiripentol efficacy against status epilepticus and associated mortality in mice
HeliyonStiripentol (STP, Diacomit©) is an antiseizure medication indicated for Dravet syndrome, a rare developmental and epileptic encephalopathy characterized by drug-resistant seizures, including status epilepticus (SE).
Vincent Castagne
exaly +3 more sources